1. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial;Jakesz;Lancet,2005
2. The ATAC Trialists' Group Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer;Howell;Lancet,2005
3. BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer;Thurlimann;Proc Am Soc Clin Oncol,2005
4. The Intergroup Exemestane Study: a randomised trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen—updated survival analysis;Coombes;Breast Cancer Res Treat,2004
5. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Preliminary results of the Italian Tamoxifen Anastrozole (ITA) trial;Boccardo;J Clin Oncol,2005